PDCD1 and non-small cell lung carcinoma: After fifteen weeks of intrapleural administration, the control rate of pleural effusion in patients with non-small-cell lung cancer (NSCLC) was 66.7% and the expression of PD-1 on the surface of cytotoxic T lymphocytes in MPE showed a decreasing trend.